Print Page  Close Window


Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged relMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.3 (6.41%)
Feb 17, 2017 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
02/07/17Orexigen Therapeutics to Speak at Upcoming Investor ConferencesPrinter Friendly Version
01/25/17Orexigen Therapeutics Announces Spanish Launch of Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Partnership with Laboratorios Farmacéuticos Rovi, S.A.Printer Friendly Version
01/06/17Orexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl extended-release tablets) Real-World Study Results in "Obesity"Printer Friendly Version
01/05/17Orexigen Therapeutics Highlights Key Business Priorities for 2017Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.